Published on 2 May 2024 on Benzinga
Organon & Co OGN reported a 5% Y/Y increase in the first quarter of 2024 revenue, reaching around $1.622 billion, beating the consensus of $1.563 billion.
Women’s Health revenue increased by 11% as reported and 12% ex-FX, driven by 34% ex-FX growth in Nexplanon led by favorable customer purchasing patterns associated with the timing of U.S. list-price adjustments, coupled with favorable price and discount rates in the U.S. and the favorable timing of tenders to markets outside of the U.S.